TNXP - Tonix Pharmaceuticals Holding Corp.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.5423
-0.0388 (-6.68%)
At close: 4:00PM EST

0.5500 +0.01 (1.42%)
After hours: 7:59PM EST

Stock chart is not supported by your current browser
Previous Close0.5811
Open0.5900
Bid0.5500 x 1000
Ask0.5900 x 900
Day's Range0.5200 - 0.5900
52 Week Range0.5200 - 5.1100
Volume808,014
Avg. Volume1,266,516
Market Cap7.703M
Beta (3Y Monthly)0.38
PE Ratio (TTM)N/A
EPS (TTM)-3.0790
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.88
Trade prices are not sourced from all markets
  • Associated Press5 days ago

    Tonix: 3Q Earnings Snapshot

    The New York-based company said it had a loss of 57 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss ...

  • GlobeNewswire5 days ago

    Tonix Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights

    New Phase 3 Trial of Tonmya® for the Treatment of PTSD to Commence First Quarter 2019 NEW YORK, Nov. 09, 2018 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix or.

  • GlobeNewswire7 days ago

    Tonix Pharmaceuticals Announces New Patent Coverage Protecting Tonmya®

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) today announced that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No. 10,117,936 to the Company on November 6, 2018. This patent, “Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride,” includes 34 claims directed to pharmaceutical compositions of eutectics of cyclobenzaprine hydrochloride and mannitol and methods of making those compositions.  This patent is expected to provide Tonix with U.S. market exclusivity until 2034. The patent is part of an expanding portfolio of patents and patent applications and other intellectual property addressing the formulation, manufacturing, and uses of Tonmya*, or TNX-102 SL, for a variety of indications including posttraumatic stress disorder, agitation in Alzheimer’s disease, and fibromyalgia.

  • GlobeNewswire8 days ago

    Tonix Pharmaceuticals Presented Results and Retrospective Analyses of Phase 3 P301 “HONOR” Study in Poster Presentation at CNS Summit 2018

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company) presented a poster at CNS Summit 2018 held November 1-4, 2018, in Boca Raton, Fla.  A poster, entitled “Time Since Trauma in PTSD: Phase 3 Multi-Center, Double-Blind, Placebo-Controlled Trial of TNX-102 SL*, a Sublingual Formulation of Cyclobenzaprine, in Military-Related PTSD (Study TNX-CY-P301)” includes results and retrospective analyses from the Phase 3 P301 study (“HONOR”). The poster presentation reports that a retrospective analysis revealed a treatment effect in participants who experienced trauma less than or equal to nine years prior to screening (approximately 50% of the modified intent-to-treat population). For this subgroup, the p-value of the primary endpoint at Week 12, using mixed model repeated measures with multiple imputation (MMRM with MI), was 0.039.

  • ACCESSWIRE13 days ago

    Today’s Research Reports on Stocks to Watch: Tonix Pharmaceuticals and ACADIA Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / November 1, 2018 / Shares of Tonix Pharmaceuticals were flying higher in Wednesday’s session on news that the company plans to start a new Phase 3 trial of Tonmya, a drug formulation ...

  • GlobeNewswire13 days ago

    Tonix Pharmaceuticals to Present at BIO-Europe International Partnering Conference

    NEW YORK, Nov. 01, 2018 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix,.

  • ACCESSWIRE14 days ago

    Healthcare Market Growth Could Fuel These Stocks

    CORAL GABLES, FL / ACCESSWIRE / October 31,2018 / The bounce back for healthcare stocks started in May 2018 but faced some selling pressure in more recent trading session as market volatility grew. As far as healthcare stocks are concerned, 2018 and most likely 2019 could be ready to see a jump in deals. According to a report* from McKinsey & Company, the number of healthcare services deals among institutional investors nearly doubled from 2012 to 2017.

  • GlobeNewswire14 days ago

    Tonix Pharmaceuticals Announces Innovative Design in Next Phase 3 Study of Tonmya® for PTSD, Following FDA Meeting

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company), today announced that it plans to start a new Phase 3 trial of Tonmya®* for the treatment of posttraumatic stress disorder (PTSD) in the first quarter of 2019, based on guidance from its recent Breakthrough Therapy Type B Clinical Guidance meeting with the U.S. Food and Drug Administration (FDA). Tonix submitted interim analysis results from the original Phase 3 HONOR study of Tonmya in military-related PTSD to support a new Phase 3 study design discussion with the FDA.

  • GlobeNewswire16 days ago

    Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in Poster Presentations at CNS Summit 2018

    NEW YORK, Oct. 29, 2018 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that it will be presenting findings and retrospective analyses from the.

  • GlobeNewswire22 days ago

    Tonix Pharmaceuticals to Present at the Dawson James Securities Small Cap Growth Conference

    NEW YORK, Oct. 23, 2018 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix,.

  • ACCESSWIRElast month

    Today’s Research Reports on Stocks to Watch: Tonix Pharmaceuticals and Vital Therapies

    NEW YORK, NY / ACCESSWIRE / October 4, 2018 / Tonix Pharmaceuticals and Vital Therapies Inc. both saw big gains in Wednesday’s session despite either company releasing any news nor there being any catalyst to set shares off. Tonix was expected to have presented this week at the MicroCap Conference. Tonix Pharmaceuticals Holding Corp. shares closed up 17.80% on Wednesday with an additional gain of 5.04% in after-hours trading.

  • GlobeNewswire2 months ago

    Tonix Pharmaceuticals to Present at the MicroCap Conference

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present and host investor meetings at the MicroCap Conference being held October 1-2, 2018, in New York City. A live webcast and subsequent archived recording of the presentation will be available under the Presentations & Events tab of the Investors section of the Tonix Pharmaceuticals website at www.tonixpharma.com.

  • GlobeNewswire2 months ago

    Tonix Pharmaceuticals to Present at Sidoti & Company Fall 2018 Investor Conference

    NEW YORK, Sept. 20, 2018-- Tonix Pharmaceuticals Holding Corp. announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present and host investor meetings at the Sidoti ...

  • GlobeNewswire2 months ago

    Tonix Pharmaceuticals Announces New Board Member, Oye Olukotun, M.D.

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix) today announced the appointment of Adeoye “Oye” Olukotun, M.D. to its Board of Directors, effective immediately.  Dr. Olukotun assumes the seat held by Dr. Ernest Mario, who has stepped down from the position of company director that Dr. Mario has held since 2011. Dr. Seth Lederman, Chief Executive Officer of Tonix commented, “We are pleased to welcome Dr. Olukotun to the Tonix Board, as he brings 30 years of biopharmaceutical operational and leadership experience that will be invaluable to Tonix as we grow the company.

  • GlobeNewswire2 months ago

    Tonix Pharmaceuticals to Present at Upcoming September Investor Conferences

    NEW YORK, Aug. 30, 2018-- Tonix Pharmaceuticals Holding Corp. announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present a company overview at two investor conferences ...

  • Zacks Small Cap Research3 months ago

    TNXP: Retrospective Analyses from HONOR and AtEase Trials Presented…

    On August 21, 2018, Tonix Pharmaceuticals Holding Corp. (TNXP) announced a poster presentation at the 2018 Military Health System Research Symposium that included results from the Phase 3 HONOR trial and retrospective analyses from the HONOR trial and the Phase 2 AtEase trial of TNX-102 SL (cyclobenzaprine HCl sublingual tablet) in patients with posttraumatic stress disorder (PTSD). In July 2018, the company announced that the HONOR trial was stopped early due to a lack of separation between the placebo group and treated group at the 12-week timepoint.

  • GlobeNewswire3 months ago

    Tonix Pharmaceuticals Announces Director Stepping Down

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix) announced today that Samuel Saks, M.D. has stepped down from the Company’s board of directors, effective August 21, 2018. Dr. Seth Lederman, Chief Executive Officer of Tonix commented, “On behalf of the Board and management, I would like to thank Sam for his many contributions and dedicated service to Tonix. “It has been my privilege to have worked with the board and management team of Tonix Pharmaceuticals,” said Dr. Saks.

  • Benzinga3 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! SPDR S&P Retail (NYSE: XRT ) could see increased volatility ...

  • GlobeNewswire3 months ago

    Tonix Pharmaceuticals Presents Results and Retrospective Analyses of Two Double-Blind, Randomized Placebo-Controlled 12-Week Studies of Tonmya® in Military-Related PTSD at the 2018 Military Health System Research Symposium

    Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix) is presenting a poster today at the 2018 Military Health System Research Symposium (MHSRS) in Kissimmee, Fla.  The poster, entitled “Effect of Time Since Trauma on Response to TNX-102 SL* (Cyclobenzaprine Sublingual Tablets) in Military-Related PTSD: Results of Two Double-Blind Randomized Placebo-Controlled Studies” includes results and retrospective analyses from the Phase 3 P301 study (“HONOR”) and the Phase 2 P201 study (“AtEase”).  TNX-102 SL, or Tonmya*, is being developed for the treatment of posttraumatic stress disorder (PTSD).  The poster can be found on the Scientific Presentations page of Tonix’s website. Tonix recently reported that the Phase 3 P301 study was stopped at the pre-planned interim analysis because it did not achieve a study continuation threshold on the primary outcome of improvement in the Clinician Administered PTSD Scale for DSM-5 (CAPS-5) at Week 12 in the modified intent-to-treat (mITT) population.  Today’s poster presentation reports that a retrospective analysis revealed a treatment effect in participants who experienced trauma less than or equal to nine years prior to screening (approximately 50% of the mITT population).  For this subgroup, the p-value of the primary endpoint at Week 12, using mixed model repeated measures with multiple imputation (MMRM with MI), was 0.039.

  • Associated Press3 months ago

    Tonix: 2Q Earnings Snapshot

    On a per-share basis, the New York-based company said it had a loss of 73 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...

  • Zacks Small Cap Research3 months ago

    TNXP: HONOR Trial Stopped Early Following Interim Analysis...

    On July 27, 2018, Tonix Pharmaceuticals Holding Corp. (TNXP) announced that the Phase 3 HONOR trial of TNX-102 SL (cyclobenzaprine HCl sublingual tablet) in patients with posttraumatic stress disorder (PTSD) has been stopped early due to a lack of separation between the placebo group and treated group at the 12-week timepoint. The company is planning to meet with the FDA (which we believe will take place during 4Q18) and will propose using the 4-week timepoint as the primary outcome measure for the next pivotal trial.

  • Benzinga4 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Amazon.com, Inc. (NASDAQ: AMZN ) was trading higher ...